Coya Therapeutics, Inc.

COYA
As of the close on Sep 25, 2026
Price
$5.08
Market cap
$119M
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How Coya Therapeutics, Inc. Makes Money

Follow each dollar of revenue through to what shareholders keep.

From revenue to net income

Pick a year or quarter. Each band's width is its dollar amount.

Source: Coya Therapeutics, Inc. — 10-Q filed Aug 11, 2026

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Apr 9, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Reported 13F positions

Each row shows what a filer reported for one date, not a current position. The link opens that filing.

Filer Report date Shares Value Filing
JANE STREET GROUP, LLC 2026-03-31 13,340 Not shown SEC filing
Caitong International Asset Management Co., Ltd 2026-03-31 3 Not shown SEC filing
Jump Financial, LLC 2026-03-31 21,000 Not shown SEC filing
BNP PARIBAS FINANCIAL MARKETS 2026-03-31 8,563 Not shown SEC filing
HRT FINANCIAL LP 2026-03-31 13,517 Not shown SEC filing
MORGAN STANLEY 2026-03-31 85,700 Not shown SEC filing
BFSG, LLC 2026-03-31 3,455 Not shown SEC filing
683 Capital Management, LLC 2026-03-31 70,000 Not shown SEC filing
Cetera Investment Advisers 2026-03-31 30,000 Not shown SEC filing
Allworth Financial LP 2026-03-31 1,000 Not shown SEC filing
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 2026-03-31 10,000 Not shown SEC filing
JONES FINANCIAL COMPANIES LLLP 2026-03-31 44,960 Not shown SEC filing
PRELUDE CAPITAL MANAGEMENT, LLC 2026-03-31 101,330 Not shown SEC filing
CITADEL ADVISORS LLC 2026-03-31 16,859 Not shown SEC filing
HighTower Advisors, LLC 2026-03-31 10,029 Not shown SEC filing
JPMORGAN CHASE & CO 2026-03-31 5,000 Not shown SEC filing
RAYMOND JAMES FINANCIAL INC 2026-03-31 11,673 Not shown SEC filing
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 2026-03-31 20,626 Not shown SEC filing
Squarepoint Ops LLC 2026-03-31 40,465 Not shown SEC filing
OCCUDO QUANTITATIVE STRATEGIES LP 2026-03-31 23,642 Not shown SEC filing
  • Each value is checked against Coya Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
  • Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.

Filer report history

Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.

  • ROYAL BANK OF CANADA: 27,436 shares reported 2025-12-31; 13,392 shares reported 2026-03-31.
  • Triumph Capital Management: 50 shares reported 2025-12-31; 50 shares reported 2026-03-31.
  • AIGH Capital Management LLC: 975,404 shares reported 2025-12-31; 975,404 shares reported 2026-03-31.
  • Long Corridor Asset Management Ltd: 38,766 shares reported 2025-12-31; 38,766 shares reported 2026-03-31.
  • MARSHALL WACE, LLP: 225,358 shares reported 2025-12-31; 225,792 shares reported 2026-03-31.
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP: 124,831 shares reported 2025-12-31; 39,316 shares reported 2026-03-31.
  • WESTWOOD HOLDINGS GROUP INC: 36,660 shares reported 2025-12-31; 36,003 shares reported 2026-03-31.
  • State of Wyoming: 4,184 shares reported 2025-12-31; 4,156 shares reported 2026-03-31.
  • UBS Group AG: 35,035 shares reported 2025-12-31; 38,564 shares reported 2026-03-31.
  • XTX Topco Ltd: 33,070 shares reported 2025-12-31; 47,338 shares reported 2026-03-31.
  • OPPENHEIMER & CO INC: 14,000 shares reported 2025-12-31; 18,000 shares reported 2026-03-31.
  • GHP Investment Advisors, Inc.: 26,171 shares reported 2025-12-31; 26,171 shares reported 2026-03-31.

Showing the 12 most recent filer reports.

25 filers have only one report here.

Independent insiders buying near the same time

  • 2024-11-11–2024-11-14: 4 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
  • 2023-01-03–2023-01-03: 7 event(s) across 7 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing )
  • 2023-01-03–2023-01-03: 7 event(s) across 7 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing )

Purchases & sales (open market or private)

SecurityCodePriceFiling
2024-11-14SNYDER DAVID S · Chief Financial OfficerCommon Stock, par value $0.0001 per shareP — Open market or private purchase+1,8007.19SEC filing
2024-11-13Swaminathan Arun · Chief Executive OfficerCommon Stock, par value $0.0001 per shareP — Open market or private purchase+5,0007.36SEC filing
2024-11-11Grossman Fred · Chief Medical OfficerCommon Stock, par value $0.0001 per shareP — Open market or private purchase+2,7107.37SEC filing
2024-11-11Swaminathan Arun · Chief Executive OfficerCommon Stock, par value $0.0001 per shareP — Open market or private purchase+5,0007.34SEC filing
2023-08-22Lee Ann · DirectorCommon Stock, par value $0.0001 per shareP — Open market or private purchase+1,0003.62SEC filing
2023-01-03Villalobos Anabella · DirectorCommon Stock, par value $0.0001 per shareP — Open market or private purchase+10,000unknownSEC filing
2023-01-03Villalobos Anabella · DirectorWarrant to Purchase Common StockP — Open market or private purchase+5,000unknownSEC filing
2023-01-03Hepner Adrian · Chief Medical OfficerCommon Stock, par value $0.0001 per shareP — Open market or private purchase+10,000unknownSEC filing

Showing 8 of 10 rows

Grants, exercises, tax & gifts

SecurityCodeFiling
2026-04-09Pavao Mark H · DirectorStock Option (right to buy)A — Grant, award, or other acquisition+10,000SEC filing
2026-01-22Grossman Fred · Chief Medical OfficerStock Option (right to buy)A — Grant, award, or other acquisition+140,041SEC filing
2026-01-22SNYDER DAVID S · Chief Financial OfficerStock Option (right to buy)A — Grant, award, or other acquisition+140,041SEC filing
2026-01-22Berman Howard · Executive ChairmanStock Option (right to buy)A — Grant, award, or other acquisition+15,257SEC filing
2026-01-22Swaminathan Arun · Chief Executive OfficerStock Option (right to buy)A — Grant, award, or other acquisition+293,983SEC filing
2026-01-02Weinand Dieter · DirectorStock Option (right to buy)A — Grant, award, or other acquisition+10,000SEC filing
2026-01-02GOLDSTEIN DOV A MD · DirectorStock Option (right to buy)A — Grant, award, or other acquisition+10,000SEC filing
2026-01-02ROSS WILBUR L JR · DirectorStock Option (right to buy)A — Grant, award, or other acquisition+10,000SEC filing

Showing 8 of 14 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.